Molecular genetic testing of patients with monogenic diabetes and hyperinsulinism

https://doi.org/10.1016/j.ymgme.2014.12.304Get rights and content

Highlights

  • Sequencing of the largest North American cohort of NDM, CHI, & MODY patients

  • Mosaicism detected in one MODY family

  • Possible digenic HNF1A and GCK inheritance detected

  • 23 novel variants in HNF1A, GCK, HNF4A, ABCC8, KCNJ11, and INS reported

  • Interpretation of a third of the variants changed over the 4-year review period.

Abstract

Genetic sequencing has become a critical part of the diagnosis of certain forms of pancreatic beta cell dysfunction. Despite great advances in the speed and cost of DNA sequencing, determining the pathogenicity of variants remains a challenge, and requires sharing of sequence and phenotypic data between laboratories. We reviewed all diabetes and hyperinsulinism-associated molecular testing done at the Seattle Children's Molecular Genetics Laboratory from 2009 to 2013. 331 probands were referred to us for molecular genetic sequencing for Neonatal Diabetes (NDM), Maturity-Onset Diabetes of the Young (MODY), or Congenital Hyperinsulinism (CHI) during this period. Reportable variants were identified in 115 (35%) patients with 91 variants in one of 6 genes: HNF1A, GCK, HNF4A, ABCC8, KCNJ11, or INS. In addition to identifying 23 novel variants, we identified unusual mechanisms of inheritance, including mosaic and digenic MODY presentations. Re-analysis of all reported variants using more recently available databases led to a change in variant interpretation from the original report in 30% of cases. These results represent a resource for molecular testing of monogenic forms of diabetes and hyperinsulinism, providing a mutation spectrum for these disorders in a large North American cohort. In addition, they highlight the importance of periodic review of molecular testing results.

Introduction

Genetic sequencing is a critical part of the diagnosis of certain forms of pancreatic beta cell dysfunction, including Maturity Onset Diabetes of the Young (MODY), Neonatal Diabetes (NDM), and Congenital Hyperinsulinism (CHI). MODY is the most common form of monogenic diabetes, accounting for 2–5% of all patients with diabetes [1]. Initially defined by the presence of a positive family history, absence of insulin dependence, and early onset of symptoms (< 25 years), the diagnosis of MODY is now defined by molecular genetic testing [2]. Mutations in 11 genes have now been described as causing MODY, although mutations in just three (HNF1A, GCK, HNF4A) account for over 70% of patients [3]. Only 5–20% of patients with MODY are correctly diagnosed [4]. Because patients with MODY are frequently young and non-obese, they are often misdiagnosed as having type 1 diabetes and treated with insulin [2], [5]. Misdiagnosis with type 2 diabetes is possible as well [2], [5]. Since the majority of MODY patients can be managed with oral hypoglycemic agents or diet alone, accurate molecular diagnosis of these patients is critical [2], [6], [7].

NDM is a disorder of pancreatic beta cell function characterized by hyperglycemia within the first 6 months of life. There are a variety of syndromic forms, which are categorized by the presence of other abnormalities, but most patients with NDM are non-syndromic and are classified as having either transient or permanent NDM. Transient NDM patients typically have hyperglycemia that resolves by 18 months; ~ 70% of these patients have an imprinting abnormality at 6q24 [5]. The hyperglycemia in patients with permanent NDM typically does not resolve, and mutations in 4 different genes (KCNJ11, ABCC8, INS, GCK) account for ~ 70% of patients [8], [9], [10], [11].

CHI is characterized by hypoglycemia with inappropriately elevated insulin. CHI can present in the neonatal period with severe hypoglycemia, although milder, childhood-onset presentations occur as well. Mutations in eight different genes, all of which function in the regulation of insulin secretion, have now been described as causing CHI, although mutations in just three (ABCC8, KCNJ11, GCK) account for ~ 50% of patients [12].

Here we report the results of diagnostic testing for pancreatic beta cell disorders at the Seattle Children's Molecular Genetics Laboratory (SCHMGL) over a 4-year period. SCHMGL was the first laboratory in North America to offer such testing. Reportable variants were identified in 115 of 331 (35%) probands referred to us. A total of 91 variants were identified in 6 genes sequenced (HNF1A, GCK, HNF4A, ABCC8, KCNJ11, or INS), 23 of which are novel and not previously reported. We provide evidence for digenic and mosaic MODY presentations. Re-analysis of all variants using the latest available databases and literature altered variant interpretation in about 30% of cases. These results expand the spectrum of known variants associated with MODY, NDM, and CHI, and provide a resource for variant interpretation based on the largest North American cohort reported to date. In addition, they highlight the importance of periodic review of molecular testing results, in particular of variants of uncertain significance.

Section snippets

Study design

The SCHMGL is a reference diagnostic laboratory that has been performing molecular diagnostic testing for MODY, NDM, and CHI since September 2009. Referrals come from physicians and other laboratories within North America. After approval by the Seattle Children's Hospital Institutional Review Board, all molecular test results sent to SCHMGL for MODY, NDM, and CHI testing from 9/2009 to 10/2013 were reviewed. A total of 331 probands were referred for testing during this period. Reasons for

Molecular genetic testing

A total of 331 probands were referred to the SCHMGL for molecular genetic sequencing of HNF1A, GCK, HNF4A, ABCC8, KCNJ11, or INS during the 4-year review period. For 184 probands (55%) the indication for diagnostic testing was some form of hyperglycemia; for 30 (9%) probands the indication was hypoglycemia/hyperinsulinism, and for 117 probands (35%) no clinical information was available. Ages of the patients at the time of testing ranged from birth to 67 years; 53% of the cohort was female.

Discussion

We present the results of molecular genetic testing for disorders of pancreatic beta cell function (MODY, NDM, and CHI) from 331 probands, the largest North American cohort of these patients reported to date. Reportable variants were identified in 35% of patients. In addition to providing a useful resource for variant classification, our results highlight some of the major hurdles facing molecular diagnostic testing, including challenges with variant interpretation, paucity and heterogeneity of

Contributions

M.Z. and J.N. performed DNA extractions, PCR and sequencing analysis. J.T.B., V.V., and S.H. researched data and performed variant interpretation. P.G. contributed clinical information. J.T.B., V.V., and S.H. wrote and edited the manuscript. S.H. developed the diagnostic test and supervised the project, and serves as the guarantor of the manuscript.

Conflict of interest

There are no conflicts of interests.

Acknowledgments

This work was funded by the NIH/NIGMS Medical Genetics Training Grant T32 GM007454 (J.T.B.). The authors would like to thank all of the providers, in particular Drs. David Cobb, who referred their patients to us and the patients and their families for participating. We also thank Drs. Catherine Pihoker and Lisa Gilliam at the University of Washington and Dr. Sian Ellard for their help in validating the clinical tests.

References (74)

  • R. Murphy et al.

    Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes

    Nat. Clin. Pract. Endocrinol. Metab.

    (2008)
  • M. Shepherd et al.

    A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients

    Diabet. Med.

    (2009)
  • E.R. Pearson et al.

    Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations

    N. Engl. J. Med.

    (2006)
  • A.P. Babenko et al.

    Activating mutations in the ABCC8 gene in neonatal diabetes mellitus

    N. Engl. J. Med.

    (2006)
  • J. Stoy et al.

    Insulin gene mutations as a cause of permanent neonatal diabetes

    Proc. Natl. Acad. Sci. U. S. A.

    (2007)
  • M. Polak et al.

    Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group

    Diabetes

    (2008)
  • Familial hyperinsulinism

  • S.E. Plon et al.

    Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

    Hum. Mutat.

    (2008)
  • K. Mohnike et al.

    Clinical and genetic evaluation of patients with KATP channel mutations from the German registry for congenital hyperinsulinism

    Horm. Res. Paediatr.

    (2014)
  • F.O. Desmet et al.

    Human Splicing Finder: an online bioinformatics tool to predict splicing signals

    Nucleic Acids Res.

    (2009)
  • A.L. Gloyn et al.

    Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes

    N. Engl. J. Med.

    (2004)
  • J. Hager et al.

    Six mutations in the glucokinase gene identified in MODY by using a nonradioactive sensitive screening technique

    Diabetes

    (1994)
  • M. Stoffel et al.

    Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus

    Proc. Natl. Acad. Sci. U. S. A.

    (1992)
  • M.P. Lopez-Garrido et al.

    Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing

    Clin. Endocrinol.

    (2013)
  • M. Capuano et al.

    Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy

    PLoS ONE

    (2012)
  • K.K. Osbak et al.

    Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

    Hum. Mutat.

    (2009)
  • T. Yorifuji et al.

    Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus

    Pediatr. Diabetes

    (2012)
  • S. Shahawy et al.

    A pathway to insulin independence in newborns and infants with diabetes

    J. Perinatol.

    (2011)
  • K. Colclough et al.

    Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia

    Hum. Mutat.

    (2013)
  • R.R. Kapoor et al.

    Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism

    Eur. J. Endocrinol.

    (2013)
  • J.R. Lupski et al.

    Exome sequencing resolves apparent incidental findings and reveals further complexity of SH3TC2 variant alleles causing Charcot–Marie–Tooth neuropathy

    Genome Med.

    (2013)
  • T. Yorifuji et al.

    Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys: phenotypically discordant recurrence of a mutation in the hepatocyte nuclear factor-1beta gene due to germline mosaicism

    J. Clin. Endocrinol. Metab.

    (2004)
  • E.L. Edghill et al.

    Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood

    Diabetes

    (2008)
  • A.L. Gloyn et al.

    Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel

    J. Clin. Endocrinol. Metab.

    (2004)
  • F. Godart et al.

    Identification of seven novel nucleotide variants in the hepatocyte nuclear factor-1alpha (TCF1) promoter region in MODY patients

    Hum. Mutat.

    (2000)
  • W.L. Awa et al.

    Genetic and clinical characteristics of patients with HNF1A gene variations from the German–Austrian DPV database

    Eur. J. Endocrinol.

    (2011)
  • E.P. Consortium et al.

    An integrated encyclopedia of DNA elements in the human genome

    Nature

    (2012)
  • Cited by (27)

    • American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update

      2022, Endocrine Practice
      Citation Excerpt :

      Monogenic diabetes accounts for 1% to 3% of DM diagnosed under 30 years of age (∼0.4% of all DM) and frequently occurs in pubertal children or young adults <35 years of age. Many, but not all, will have a family history over 3 generations.42-47 Monogenic diabetes includes neonatal diabetes, MODY, and diabetes associated with a variety of syndromes, including mitochondrial disorders, lipodystrophy syndromes, Wolfram syndrome, and many others.

    • Next- generation sequencing is an effective method for diagnosing patients with different forms of monogenic diabetes

      2022, Diabetes Research and Clinical Practice
      Citation Excerpt :

      This showed a high frequency of monogenic diabetes of more than 36% in the selected group of patients and more than 46% in the first-degree relatives of probands. These findings are consistent with observations made in the USA and Canada, indicating a 35–40% contribution of various forms of monogenic diabetes among all diabetes cases in patients [5,17]. A study conducted in Europe confirmed monogenic diabetes in about 16% of patients, and among patients of Euro-Caucasian origin even in more than 23% of patients [18].

    • A case of digenic maturity onset diabetes of the young with heterozygous variants in both HNF1Α and HNF1Β genes

      2021, European Journal of Medical Genetics
      Citation Excerpt :

      To the best of our knowledge, only six cases of patients with MODY and pathogenic variants in more than one of the described causative genes have been reported up to now. ( Karges et al., 2007; Shankar et al., 2013; Forlani et al., 2010; Beijers et al., 2009; Bennett et al., 2015; Lopez-Garrido et al., 2013). In a UK study, the prevalence of GCK, HNF1A, HNF4A and HNF1B pathogenic variants among the pediatric diabetes population was found to be 1%, 0.6%, 0.5% and 0.1% respectively (Shepherd et al., 2016).

    • Variation in the clinical and genetic evaluation of undervirilized boys with bifid scrotum and hypospadias

      2017, Journal of Pediatric Urology
      Citation Excerpt :

      Although such undervirilization has been well managed surgically, progress in diagnosis has lagged. In many diseases, genetic testing to determine etiology has led to significant progress in understanding pathogenesis and even to targeted treatment, such as in congenital cardiac disease [7], intellectual disability [8], and hyperinsulinism/neonatal diabetes mellitus [9]. Recently, studies have focused on the genetics of DSD that result in frankly ambiguous genitalia [10–13], but relatively few studies have focused on the genetics of milder cases of undervirilization.

    • A three-step programmed method for the identification of causative gene mutations of maturity onset diabetes of the young (MODY)

      2016, Gene
      Citation Excerpt :

      Sanger sequencing, however, is expensive and time-consuming when used to screen numerous genes in potential diabetes patients. In previous studies on the identification of MODY, suspected causative gene mutations were not confirmed by gene-editing protein function detection (Alkorta-Aranburu et al., 2014; Bennett et al., 2015). With this in mind, we developed a low cost and accurate programmed three-step method that combines genetic screening with gene-editing protein function testing.

    View all citing articles on Scopus
    View full text